APAC Pharmacogenetic Testing Market - Industry Trends and Forecast to 2031
The Asia-Pacific pharmacogenetic testing market is expected to reach USD 2,049.35 million by 2030 from USD 970.29 million in 2022, growing at a CAGR of 10.0% during the forecast period of 2023 to 2030.
Market SegmentationAsia-Pacific Pharmacogenetic Testing Market, By Type (Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, and Single Gene Tests), Gene Type (CYP2C19, CYP2D6, CYP2C9 AND VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX AND MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and Others), Drug Type (Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, and Over-the-Counter Medications), Sample (Blood and Saliva), Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology, and Others), Application (Clinical Practice, Drug Development, and Drug Regulation), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Research Centres and Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, and Direct-to-Customer Services), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Global Pharmacogenetic Testing Market Dynamics
Driver
• Rapid technological advancement and miniaturization
Restrain
• Environment and health concerns
Opportunity
• Rising research and development and innovative technologies
Market Players
Some of the major market players operating in the Asia-Pacific pharmacogenetic testing market are: • Thermo Fisher Scientific
• Sonic Healthcare
• BGI
• QIAGEN
• Illumina, Inc